SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.78 CNY | +0.15% |
|
-1.31% | -15.25% |
| Apr. 15 | Grifols Plans to Appoint Independent Directors Only to Audit, Compensation Committees | MT |
| Apr. 10 | Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake | RE |
| Sales 2023 * | 7.8B 1.08B | Sales 2024 * | 9.08B 1.25B | Capitalization | 44.39B 6.13B |
|---|---|---|---|---|---|
| Net income 2023 * | 2.17B 300M | Net income 2024 * | 2.52B 349M | EV / Sales 2023 * | 5.69 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 4.89 x |
| P/E ratio 2023 * |
20.9
x | P/E ratio 2024 * |
17.8
x | Employees | 3,121 |
| Yield 2023 * |
0.55% | Yield 2024 * |
0.59% | Free-Float | 68.13% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +0.15% | ||
| 1 week | -1.31% | ||
| Current month | -4.51% | ||
| 1 month | -8.38% | ||
| 3 months | -5.31% | ||
| 6 months | -3.28% | ||
| Current year | -15.25% |
1 week
6.70
6.97
1 month
6.707.45
Current year
5.938.60
1 year
5.938.68
3 years
4.988.68
5 years
4.9811.16
10 years
4.9826.67
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Xu
CEO | Chief Executive Officer | 60 | 11-12-31 |
Le Qi Chen
DFI | Director of Finance/CFO | 37 | 21-10-25 |
Wei Bing Hu
CHM | Chairman | 60 | 03-03-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 20-05-19 | |
Yue Wen Zheng
BRD | Director/Board Member | 62 | 07-04-26 |
David Ian Bell
BRD | Director/Board Member | 70 | 20-05-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.71% | 2 M€ | -14.14% | ||
| 0.69% | 2 M€ | -20.57% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 6.78 | +0.15% | 35,363,490 |
| 24-04-12 | 6.77 | -0.59% | 23,206,880 |
| 24-04-11 | 6.81 | -0.29% | 14,788,340 |
| 24-04-10 | 6.83 | -1.87% | 21,240,790 |
| 24-04-09 | 6.96 | +1.31% | 25,147,950 |
End-of-day quote Shenzhen S.E., April 14, 2024
More quotes
Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin).
China accounts for 96.6% of net sales.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.78
CNY
Average target price
7
CNY
Spread / Average Target
+3.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.25% | 6.22B | |
| -4.17% | 86.99B | |
| +4.34% | 40.68B | |
| -24.59% | 28.61B | |
| +51.27% | 24.1B | |
| -5.76% | 17.37B | |
| -32.11% | 13.72B | |
| -5.10% | 12.49B | |
| -15.24% | 12B | |
| -3.22% | 7.94B |
- Stock Market
- Equities
- 002252 Stock
